Printer Friendly

Idun to Host First Conference Focused on Commercial Opportunities of Apoptosis; - Apoptosis: Commercial Opportunities, April 28 - May 1, 2002 in San Diego -.

SAN DIEGO -- Idun Pharmaceuticals, Inc. will host a landmark four day conference, April 28 - May 1, 2002, entitled "Apoptosis: Commercial Opportunities." The event will bring together an international group of academic and industry experts and include presentations from luminaries in the field, including H. Robert Horvitz, Ph.D., Massachusetts Institute of Technology, John J. Alam, M.D., Vertex Inc., and Richard N. Kitsis, M.D., Albert Einstein College of Medicine. Apoptosis, or programmed cell death, plays a role in more than 70% of all human diseases including the top three killers in the U.S.: heart disease, stroke and cancer. The conference will blend knowledge of the molecular biology of the apoptosis pathway with its commercial applications in the pharmaceutical, diagnostic and agricultural fields.

"We are excited to host the first and only annual Apoptosis Conference focused on commercial opportunities," stated Steven J. Mento, Ph.D., President and CEO of Idun Pharmaceuticals. "We're bringing together world renowned leaders in apoptosis for this event to highlight the advances and the promise for new and effective therapies for diseases, such as cancer, cardiovascular diseases, CNS diseases and inflammation."

The invited speakers represent an international list of who's who in apoptosis research and development, including representatives from the following companies and institutions: Abbott Laboratories, Genentech, Inc., UCSF Comprehensive Cancer Center, Harvard Medical School, UCSD Department of Medicine and Salk Institute, Merck Frosst, Cell Pathways, Inc., Walter and Eliza Hall Institute of Medical Research (WEHI), La Jolla Institute for Allergy and Immunology, The Burnham Institute, University of Texas Southwestern Medical Center, Aegera Oncology, Inc., Gemin X, Albert Einstein College of Medicine, University of Cambridge, University of Nebraska Lincoln, ChromaVision Medical Systems, and University Hospital Maastricht.

The conference will focus on leveraging apoptosis to develop treatments for disease and will include presentations on the latest in apoptosis research, how apoptosis is related to important diseases and approaches to the clinic. The agenda for "Apoptosis: Commercial Opportunities" includes the following topics:
 -- Manipulating Apoptosis in Heart Disease
 -- Role of Caspases in Neurologic Disease
 -- Targeting Death Receptors in Cancer
 -- Structural Studies of Proteins Involved in Regulating Apoptosis
 -- Apoptosis and Plant Disease/Stress Response: Challenges and

For additional information and to register for "Apoptosis: Commercial Opportunities," please visit or call 858/623-1330.

Idun Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, CA. It creates innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Idun believes that controlling the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders and cardiovascular disease. The company has a commercialization strategy encompassing: strategic collaborations with major pharmaceutical companies; internal, independent development of selected small molecule therapeutics; and out-licensing of diagnostics, gene therapies, and bioproduction technologies. Idun has a broad patent portfolio covering the fundamental and core technologies involved in the regulation of cell death and has established partnerships with Abbott Laboratories in cancer, with Elan Corporation, plc in stroke, and Becton Dickinson and Company in research reagents.

Some of the statements in this press release are forward-looking statements and do not guarantee future performance and involve risks and uncertainties. Actual results may differ substantially from the results that the forward-looking statements suggest for various reasons. These forward-looking statements are made only as of the date of this press release.


Contact: Steven J. Mento, Ph.D., President and CEO of Idun Pharmaceuticals, +1-858-623-1330; or Kathy Witz Sweeney of Mentus, +1-858-455-5500, ext. 140,, for Idun Pharmaceuticals

COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 6, 2002
Previous Article:Mesa Air Group Reports January 2002 Traffic.
Next Article:Spectranetics Earns Net Profit of $442,000 in the Fourth Quarter; 2001 is First Profitable Year in Both Net and Operating Income.

Related Articles
Idun Acquires SMAC, a Key Apoptosis Regulating Gene.
Commercial Opportunities of Apoptosis Conference Headlines Academic and Industry Leaders; - Apoptosis: Commercial Opportunities, April 28 - May 1,...
Internationally Renowned Experts to Speak at Apoptosis Conference; - Apoptosis: Commercial Opportunities, April 28 - May 1, 2002 Hosted by Idun...
Internationally Renowned Experts Present Research on Apoptosis And Applications in Cardiovascular Disease and Cancer; - Idun Pharmaceuticals Hosts...
Idun Presents New Data on Stroke Applications of Apoptosis.
Cell Preservation Technology Improves Diagnostics, Enhances Bioproduction Of Drugs and Generates Healthier Crops; - Extensive Applications of Cell...
Idun Pharmaceuticals Granted 100th Patent in Apoptosis; Idun Extends Worldwide Dominant Position in Key Technology.
Idun Pharmaceuticals Announces Results of Successful Phase 1 Clinical Trial; - First Trial Shows Improvements in Liver Enzymes With IDN-6556 -.
Idun granted apoptosis patent.
Idun Featured at BIO 2002 Business Forum in Toronto; - Idun Pharmaceuticals Moving Forward With Clinical Trials in Hepatic Disease And Heart Attack -.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters